Skip to content
Screener

Denali Therapeutics Inc. DNLI Raw materials

Raw materials at other companies

Eli Lilly logo
Eli LillyLLY
$4.13B+31.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$610.9M-18.8%

Other financials

Income statement

See full
Revenue$3.6M—
Gross profit$3.5M—
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation

See full
Market cap$3.97B+96.3%
Enterprise value$3.8B+97.4%
P/S1,101.3×+1,096×

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0×0.0×
Current ratio8.4×-1.9×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryRawMaterialsNetOfReserves.

The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:08 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001714899-26-000097

FAQ

What is Denali Therapeutics Inc.'s raw materials?
Denali Therapeutics Inc. (DNLI) reported raw materials of $0 in Q2 2026.
What does raw materials mean?
Unprocessed materials and components purchased for use in manufacturing, valued at cost.

Ask your AI about Denali Therapeutics Inc.'s raw materials.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude